Results 91 to 100 of about 10,308 (152)

Results of TETimaX Trial of Langerhans Cell Histiocytosis Treatment and Perspectives on the Role of Imatinib Mesylate in the Era of MAPK Signaling. [PDF]

Biomedicines, 2021
Montella L, Ottaviano M, Riccio V, Picozzi F, Facchini G, Insabato L, Giuliano M, Palmieri G.   +7 more
europepmc   +1 more source

Compatibility Studies of Different Crystal Forms of Imatinib Mesylate with Pharmaceutical Excipients. [PDF]

ACS Omega
Mou Y, Zhao Y, Wen S, Li X, Zhang W, Xu X, Wang Y.   +6 more
europepmc   +1 more source

In vivo Pharmacokinetics and in vitro Release of Imatinib Mesylate-Loaded Liposomes for Pulmonary Delivery. [PDF]

Int J Nanomedicine, 2021
Xu H, Ji H, Li Z, Qiao W, Wang C, Tang J.   +5 more
europepmc   +1 more source

Toxicity assessment of imatinib mesylate and a related impurity: in vitro and in vivo approaches. [PDF]

Toxicol Res (Camb)
Rocha CFRDS, Hermmann BS, Kayser JM, Zimmermann Prado Rodrigues G, Gehlen G, Boaretto FBM, Picada JN, Fleck JD, Charão MF, Verza SG.   +9 more
europepmc   +1 more source

Multiple Eruptive Dermatofibromas Secondary to Imatinib Mesylate in a Patient with Chronic Myeloid Leukemia. [PDF]

Indian J Dermatol, 2021
Lira-Valero FJ, Godínez-Aldrete L, Pulido-Díaz N, Quintal-Ramírez MJ.   +3 more
europepmc   +1 more source

Erythema following imatinib mesylate [PDF]

British Journal of Haematology, 2003
Duncan, E, Raj, K, Mufti, G
openaire   +2 more sources

Transanal minimally invasive surgery for rectal gastrointestinal stromal tumor using articulated forceps after neoadjuvant chemotherapy with imatinib mesylate. [PDF]

Int Cancer Conf J
Masui H, Itatani Y, Okamura R, Okamoto M, Yamada A, Sakamoto Y, Hoshino N, Hida K, Obama K.   +8 more
europepmc   +1 more source

Imatinib Mesylate-Induced Acquired Dermal Melanocytosis and Acquired Bilateral Nevus of Ota-Like Macules. [PDF]

Ann Dermatol, 2021
Jang JW, Song CH, Jung YJ, Cheon DU, Koh WS, Ro YS, Ko JY.   +6 more
europepmc   +1 more source

Claudin-1 Contributes to Gastrointestinal Stromal Tumors (GIST) Resistance to Imatinib Mesylate (IM) via Regulation of FGFR-Signaling. [PDF]

Int J Mol Sci
Boichuk S, Bikinieva F, Dunaev P, Galembikova A, Mikheeva E, Valeeva E, Mani S, Khromova N, Kopnin P, Shigapova L, Deviatiiarov R, Shagimardanova E, Ryzhkin S, Sabirov A.   +13 more
europepmc   +1 more source

Imatinib Mesylate for the Treatment of Canine Mast Cell Tumors: Assessment of the Response and Adverse Events in Comparison with the Conventional Therapy with Vinblastine and Prednisone. [PDF]

Cells, 2022
Macedo TR, de Queiroz GF, Casagrande TAC, Alexandre PA, Brandão PE, Fukumasu H, Melo SR, Dagli MLZ, Pinto ACBCF, Matera JM.   +9 more
europepmc   +1 more source